KR100883566B1 - The healthy and funtional foods for the cancer prevention of using new type of solanum tuberosum l cv. gogu valley - Google Patents
The healthy and funtional foods for the cancer prevention of using new type of solanum tuberosum l cv. gogu valley Download PDFInfo
- Publication number
- KR100883566B1 KR100883566B1 KR1020080039284A KR20080039284A KR100883566B1 KR 100883566 B1 KR100883566 B1 KR 100883566B1 KR 1020080039284 A KR1020080039284 A KR 1020080039284A KR 20080039284 A KR20080039284 A KR 20080039284A KR 100883566 B1 KR100883566 B1 KR 100883566B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- valley
- potato
- solanum tuberosum
- extract
- Prior art date
Links
- 244000061456 Solanum tuberosum Species 0.000 title claims abstract description 74
- 235000002595 Solanum tuberosum Nutrition 0.000 title claims abstract description 71
- 206010028980 Neoplasm Diseases 0.000 title claims description 59
- 201000011510 cancer Diseases 0.000 title claims description 50
- 235000013305 food Nutrition 0.000 title claims description 13
- 230000002265 prevention Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 24
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
- 239000002778 food additive Substances 0.000 claims abstract description 6
- 235000013373 food additive Nutrition 0.000 claims abstract description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 4
- 244000269722 Thea sinensis Species 0.000 claims abstract 2
- 230000036541 health Effects 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 12
- 230000003449 preventive effect Effects 0.000 claims description 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 4
- 235000012149 noodles Nutrition 0.000 claims description 4
- 235000013339 cereals Nutrition 0.000 claims description 3
- 235000013527 bean curd Nutrition 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 12
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 7
- 206010017758 gastric cancer Diseases 0.000 abstract description 7
- 201000011549 stomach cancer Diseases 0.000 abstract description 7
- 208000000453 Skin Neoplasms Diseases 0.000 abstract description 5
- 201000000849 skin cancer Diseases 0.000 abstract description 5
- 235000013361 beverage Nutrition 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 32
- 235000012015 potatoes Nutrition 0.000 description 18
- 230000004069 differentiation Effects 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 244000017020 Ipomoea batatas Species 0.000 description 7
- 235000002678 Ipomoea batatas Nutrition 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- -1 severe air pollution Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 description 1
- ZCWPHDXKEDBCER-UHFFFAOYSA-N 2,5-diphenyl-2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=CC=CC=C1C1=[NH+]N(C=2C=CC=CC=2)N=N1 ZCWPHDXKEDBCER-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000257739 Dioscorea bulbifera Species 0.000 description 1
- 235000008532 Dioscorea bulbifera Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000004976 Solanum vernei Nutrition 0.000 description 1
- 241000352057 Solanum vernei Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/105—Sweet potatoes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/12—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops of potatoes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 감자의 신품종인 고구밸리 감자(Solanum tuberosum L., cv. Gogu valley) 추출물을 함유하며, 암의 예방 기능을 갖는 건강기능식품에 관한 것이다.The present invention relates to a health functional food containing a new kind of potatoes, Solanum tuberosum L. (cv. Gogu valley) extract, and has a preventive function of cancer.
우리나라는 1982년 이후 뚜렷한 선진국형 질병구조를 보이고 있다. 특히 심각한 대기 오염, 농약, 흡연, 화학제품, 잘못된 식생활(유해 식품 첨가물, 기름에 튀긴 인스턴트 식품, 과도한 지방질 음식의 섭취), 쫓기는 시간 속의 스트레스 등 수많은 발암원인에 노출되어 있다. 이러한 여러 가지 요인으로 인한 암은 단일질병으로는 가장 많은 사망원인으로 사회적인 문제점으로 등장하고 있다.Korea has shown a distinctive disease structure since 1982. In particular, they are exposed to a number of carcinogens, including severe air pollution, pesticides, smoking, chemicals, bad diets (harmful food additives, fried instant foods, and excessive fatty foods), and stress over time. Cancer caused by these various factors is the most common cause of death as a single disease and has emerged as a social problem.
각종 유해 물질이 체내에 축적되면 이것이 결국 혈액을 오염시키게 된다. 음식물의 소화작용과 대사과정에서 발생되는 유해산소(활성산소)의 생성으로 인해 세포의 변위가 발생하는데 이렇게 하여 발생된 손상된 세포의 덩어리가 암이다. 암은 제멋대로 자라고 정상조직을 파괴하는, 백해무익의 이상 조직으로서, 악성종양이라 부른다.Accumulation of various harmful substances in the body will eventually contaminate the blood. Cell displacement occurs due to the production of harmful oxygen (active oxygen), which occurs during digestion and metabolism of food, and the damaged cell mass is cancer. Cancer is an abnormal tissue of white seaweed that grows freely and destroys normal tissue, and is called a malignant tumor.
종양에는 양성과 악성의 2가지 종류가 있는데, 양성종양은 계속 자랄 뿐, 생명에는 크게 지장이 없으며, 수술만 하면 재발없이 치유된다. 그러나 악성 종양인 암은 신체의 어느 조직에서나 발생할 수 있으며, 암세포는 일반적으로 인접한 조직에 침투하여 파괴하고, 점점 순환계를 침범하여 암 발생부위로부터 멀리 떨어진 신체의 다른 부위로 전이되어 결국 숙주(예를 들면 사람)를 죽게 한다.There are two types of tumors, benign and malignant. Benign tumors continue to grow, but they do not significantly affect life, and surgery can heal without recurrence. However, cancer, a malignant tumor, can occur in any tissue of the body, and cancer cells generally penetrate and destroy adjacent tissues, gradually invade the circulatory system, and spread to other parts of the body far from the cancerous area, eventually leading to host (e.g., To kill a person).
암은 우선 크게 고형 종양과 혈액암으로 나뉜다. 백혈병과 임파종 등의 혈구세포에 생긴 암을 혈액암이라 하며, 전체 암의 약 5%를 차지한다. 나머지는 장기나 피부에 발생한 고형암이다. 후자는 다시 장기에 따라 분류한다. 예컨대 위암, 간암의 식으로 부르는 것이 그것이다. 발생한 조직에 따라서도 분류한다. 고형 암중 가장 많은 것이 상피(장관이나 기도, 요로를 덮고 있는 세포)조직에서 발생한 상피암이다. 선(샘) 상피에서 발생하면 선암이라고 한다. 일부는 근육이나 뼈 등에서 발생하며, 이를 육종이라 한다. 예컨대 위의 선상피에 암이 발생했을 때 위 선암이라 하며, 위의 근육부위에 암이 발생했을 때 위 육종이라고 한다.Cancer is divided into solid tumors and blood cancers. Cancers in blood cells such as leukemia and lymphoma are called hematologic cancers, accounting for about 5% of all cancers. The rest are solid cancers of the organs and skin. The latter are again classified according to organs. For example, it is called stomach cancer and liver cancer. It is also classified according to the tissue that occurred. The most common solid cancer is epithelial cancer that occurs in the tissues of the epithelium (the cells that cover the intestines, respiratory tract, and urinary tract). It occurs in glandular epithelium and is called adenocarcinoma. Some occur in muscles or bones, and this is called sarcoma. For example, when cancer occurs in the epithelium of the stomach, it is called stomach adenocarcinoma, and when cancer occurs in the muscles of the stomach, it is called stomach sarcoma.
암을 현미경으로 본 형태에 따라 모양이 양순해 보이면 분화도가 좋은, 혹은 분화도가 낮은(분화도 1) 암이라 하며, 예후가 좋다. 정반대로 위험해 보이면 분화 도가 나쁜, 혹은 높은(분화도 3) 암이라고 하며, 예후가 나쁘다. 분화도가 2인 중간 형이 가장 많다. 조기 발견된 암은 대부분 분화도가 좋은 암들이다.When the cancer looks smooth in accordance with the form seen under a microscope, it is called a cancer with a good degree of differentiation or a low degree of differentiation (differentiation degree 1). Conversely, if it looks dangerous, it is called a differentiation or a high (differentiation 3) cancer, and the prognosis is bad. The middle type with the highest degree of differentiation is most common. Early cancers are mostly cancers with good differentiation.
암은 단계별로 발생하며 시간 경과에 따라 더 악성으로 진행이 된다. 발병 단계에 따라 암을 분류할 수 있으며, 이를 발전시킨 개념이 병기(stage)이다. 암이 되기 전의 단계를 전암병변이라 한다. 전암병변 중 일부는 형태가 완전한 암과 똑 같으나 상피 내에만 머물러 있으며, 이를 상피내암, 혹은 0기 암이라고 한다.Cancer develops in stages and progresses more malignant over time. Cancer can be classified according to the stage of onset, and the concept of development is stage. The stage before cancer is called precancerous lesion. Some of the precancerous lesions are identical in form to complete cancers, but remain in the epithelium and are called epithelial cancer or stage 0 cancer.
암중 가장 초기 암은 1기암으로서 침윤 정도가 경미하며, 2기암은 발생한 장기 내에 머물러 있으나 정상 조직을 뚜렷하게 침범한 경우이고, 3기암은 발생한 장기를 거의 관통하거나 주변 장기를 침범한 경우이고, 4기암은 임파선이나 원위 장기로 전이된 경우이다.The earliest of the cancers is stage 1 cancer with a slight degree of invasion, stage 2 cancer stays in the organ where it occurred, but it clearly invades normal tissue, stage III cancer almost penetrates the surrounding organ or invades surrounding organs. Is metastasis to lymph nodes or distal organs.
암의 치료법에는 크게 국소 치료법과 전신 치료법이 있으며, 선택은 암의 병기와 환자의 전신 상태, 환자의 소망과 치료하는 의사의 판단에 따라 치료법이 결정된다. 국소 치료법은 원발 암을 절제 내지 파괴하는 치료이며, 병기가 낮은 암, 특히 1-2기암일 때에 뚜렷한 가치가 있다. 여기에는 피부 절개하에 암을 그 암덩어리가 있는 장기와 주변 임파선까지 포함해서 함께 절제하는 소위 근치적 절제술이 가장 많이 시술된다. 한편 최근에는 내시경이나 레이저, 동결장비 등의 기구를 이용하여 암만 절제하고, 장기는 살리는 소위 보존적 수술요법도 최근에는 유행하고 있다. 국소암의 절제술 후 미세 전이암이 발견되거나, 분화도가 나쁠 때에는 다음의 전신 치료법이 추가된다. 전신 치료법은 전신으로 퍼진 전이 암을 치료하는 것이며, 4기나 3기암에서 선택된다. 여기에는 항암 화학요법과 면역요법, 유전자요법, 세포요법 등이 포함된다.There are largely local and systemic therapies for the treatment of cancer, and the choice of treatment depends on the stage of cancer, the general condition of the patient, the desire of the patient, and the judgment of the treating physician. Topical therapies are the resection or destruction of the primary cancer and are of significant value when the stage is low, especially stage 1-2 cancer. The most common treatment is the so-called radical resection, which involves the removal of cancer under the skin incision, including the cancerous organs and the surrounding lymph nodes. On the other hand, recently, so-called conservative surgery to relieve cancer by using an instrument such as an endoscope, a laser, a freezing device, and save an organ is also popular in recent years. The following systemic treatments are added when micro-metastatic cancer is found after resection of local cancer, or when the degree of differentiation is poor. Systemic treatment is to treat metastatic cancer that has spread throughout the body and is selected in stage 4 or 3 cancers. This includes chemotherapy, immunotherapy, gene therapy, and cell therapy.
가장 널리 시도되어 온 것이 항암 화학요법으로, 이는 정상세포와 암세포 간의 약에 대한 감수성의 차를 이용하여 정상세포에 대한 독성은 비교적 적고, 암세포에 대해서는 보다 선택적으로 작용하지만, 정상세포도 어느 정도의 손상을 받기 때문에 부작용이 나타나게 된다. 항암제는 분열이 빠른 세포에는 어디라도 작용하는 성질이 있기 때문에 빨리 분열하는 암세포에만 작용하는 것이 아니라 정상세포인 골수ㆍ위장관ㆍ모근세포도 역시 분열이 빠르므로 항암제의 영향을 받게 된다.The most widely attempted chemotherapy is the use of drug sensitivity between normal and cancer cells, which is relatively less toxic to normal cells and more selective for cancer cells, but also to some extent normal cells. The damage causes side effects. Since anti-cancer drugs have a characteristic of acting anywhere in fast-dividing cells, they act not only on rapidly dividing cancer cells but also bone marrow, gastrointestinal tract, and hair follicle cells, which are normal cells, are also affected by anti-cancer drugs.
따라서 이런 항암제의 공통된 부작용으로 일시적인 혈구 감소, 구역질, 구토, 설사, 식욕감퇴 및 탈모 등이 나타나게 된다. 그리고 다른 문제점은 암이 흔히 항암 화학제에 내성을 보인다는 것이다. 오늘날 항암제로 치유 가능한 암은 혈액암과 일부 소아암, 고환암 밖에 없으며, 나머지 폐암이나 위암, 간암 등 대다수의 성인 고형암은 약 3분의 1에서 암용적이 줄어들고 생존이 다소 연장되는 효과밖에 없어 발암물질의 생성을 억제 할 수 있는 의약 및 건강기능식품의 개발이 요구되어 왔다.Therefore, common side effects of these anticancer drugs include temporary blood cell loss, nausea, vomiting, diarrhea, loss of appetite, and hair loss. And another problem is that cancer is often resistant to anticancer chemicals. Today, the only cancer that can be cured by anticancer drugs is blood cancer, some childhood cancers, testicular cancer, and most adult solid cancers, such as lung cancer, stomach cancer, and liver cancer, have about one-third less cancer volume and longer survival. The development of medicines and health functional foods that can suppress production has been required.
감자는 남미 안데스지방이 원산지로서 구황작물로 유용한 작물이다. 감자는 생육기간이 짧고 단위 면적 당 생산량이 비교적 높고 환경적응성도 비교적 강하기 때문에 세계 130여개 나라에서 재배되고 있는 벼, 밀가루, 옥수수 다음으로 가는 세계 4대 식량작물 중의 하나이다. 감자는 일부 국가에서는 주식으로서도 중요할 뿐 만 아니라, 쌀과 보리 같은 다른 작물에 비해 저 칼로리면서 비타민 C, B1, B2, 니아신 등의 영양소가 거의 채소에 가깝기 때문에 다양한 가공제품을 만드는데 이용하기 위하여 감자의 일반적인 영양학적인 분석과, 항산화활성과 같은 생리활성에 대한 연구들이 많이 되어 있으며, 음식문화가 서구화됨에 따라서 감자의 소비는 더 한층 증가하는 추세에 있다. 이러한 소비 증가에 따라서 좀더 건강지향적인 감자 품종의 개발이 필요하게 되었다.Potatoes are native to the Andes of South America and are useful crops for coarse grain crops. Potatoes are one of the four largest food crops next to rice, wheat and corn, which are grown in more than 130 countries because of their short growing period, relatively high yields per unit area, and relatively high environmental adaptability. Potatoes are not only important as staple foods in some countries, but they are also low in calories compared to other crops such as rice and barley, and are used to make a variety of processed products because nutrients such as vitamins C, B 1 , B 2 , and niacin are almost close to vegetables. For this reason, there are many studies on the general nutritional analysis of potatoes and physiological activities such as antioxidant activity, and the consumption of potatoes is increasing further as the food culture is westernized. This increase in consumption necessitates the development of healthier potato varieties.
최근의 국제농업환경의 변화로 식량전쟁 또는 종자전쟁에 대한 압박이 더욱더 가해지고 있으며, 식량이 미래의 무기가 될 것이기 때문에 각국은 식량작물과 관련된 품종권 보호에 총력을 기울이고 있는 상황이다. 한국 또한 2002년에 국제식물신품종 보호연맹인 UPOV 에 가입하였고, 품종보호기간도 국가별로 약간씩 다르지만 최소 18년에서 35년에 걸친 품종보호 제도가 법제화 되었다.Recent changes in the international agricultural environment are putting increasing pressure on food wars and seed wars, and countries are focusing their efforts on protecting crop rights in relation to food crops because food will become the weapon of the future. Korea also joined UPOV, a new plant protection international federation in 2002, and the protection period for varieties varies slightly from country to country, but at least 18 to 35 years have been enacted.
이러한 상황에서 본 발명자들은 다양한 기능성 감자 신품종 개발하여 국가 품종으로 등록(국립종자관리원, 신품종 15종 및 출원 4 품종)하고 외국 감자 품종 들(수미/미국품종 Superior, 대지/일본품종 大地, 대서/미국품종 Atlantic)을 대체하고 있을 뿐만 아니라, 미국, 캐나다, 프랑스, 러시아, 몽골, 중국, 카자스탄, 인도 등지에서 시험재배를 진행시키고 있다.In this situation, the inventors developed various functional potato varieties and registered as national varieties (National Seed Administration, 15 new varieties and 4 varieties of application), and foreign potato varieties (Sumi and American varieties Superior, Motherland and Japanese varieties 大地, Atlantic / USA) In addition to replacing the cultivar Atlantic, they are also undergoing trial cultivation in the United States, Canada, France, Russia, Mongolia, China, Kazakhstan and India.
감자는 민간에서 많은 종류의 질환에 유용하게 사용되고 있는 것으로 전해진다. 본 발명자들은 감자를 개량하여 신품종 감자를 개발한 바 있으며, 본 발명자들에 의하여 개발된 신품종 감자는 각각의 신품종마다 그 효능을 달리하고 있다. 즉, 본 발명자들에 의하여 개발된 감자 신품종 중에서 대한민국 등록특허공보 제628417호에 신품종 밸리감자(보라밸리, 쥬스밸리, 다솜밸리, 고구밸리)가 인체 장기능 강화에 효능이 있음이 공지되어 있으며, 대한민국 등록특허공보 제654231호에는 고구밸리 품종의 감자(Solanum tuberosum L cv. Gogu Valley)에서 분리된 펩타이드가 항균작용이 탁월한 것이 공지되어 있고, 대한민국 등록특허공보 제654232호에는 골든밸리 품종의 감자(Solanum tuberosum L cv. Golden Valley)에서 분리된 펩타이드가 항균작용이 우수한 것이 공지되어 있다. 또한 대한민국 등록특허공보 제583192호에는 보라밸리 품종의 감자(Solanum tuberosum L., cv Bora valley) 추출물의 항산화제가 개시되어 있으며, 대한민국 등록특허공보 제709238호에는 보라색 감자(Solanum tuberosum L., cv Bora valley)의 에탄올 추출물이 비만세포가 분화되는 것을 차단하고 비만세포로 분화하는 렙틴(leptin) 단백질을 감소시킴으로써 비만억제 작용을 갖는다는 것이 공지되어 있다.Potatoes are said to be useful in many diseases in the private sector. The present inventors have developed new varieties of potatoes by improving potatoes, and the new varieties of potatoes developed by the present inventors have different efficacy for each new varieties. That is, it is known that the new varieties of Valley Potato (Bora Valley, Juice Valley, Dasom Valley, Gogu Valley) are effective in enhancing human intestinal function among the new potato varieties developed by the present inventors. Korean Patent Publication No. 654231 is known that the peptide isolated from the potato ( Solanum tuberosum L cv. Gogu Valley) excellent antibacterial activity, the Republic of Korea Patent Publication No. 654232, the potato of the Golden Valley variety ( It is known that peptides isolated from Solanum tuberosum L cv. In addition, Korean Patent Publication No. 583192 discloses an antioxidant of Borlan valley varieties Potato ( Solanum tuberosum L., cv Bora valley) extract, Republic of Korea Patent No. 709238, Purple Potato ( Solanum tuberosum L., cv Bora) It is known that the ethanol extract of the valley has an anti-obesity effect by blocking mast cells from differentiating and reducing leptin protein that differentiates into mast cells.
한편, 대한민국 공개특허공보 제2001-29185호에는 감자가 고혈압, 심장병, 변비증, 간염 및 기타 미생물을 억제하여 항박테리아 작용, 항암작용이 있음을 기재하고 있으나, 그 효능에 대하여는 전혀 알 수 없다.On the other hand, Korean Patent Laid-Open Publication No. 2001-29185 discloses that potato has antibacterial and anticancer effects by inhibiting hypertension, heart disease, constipation, hepatitis and other microorganisms, but its efficacy is unknown at all.
본 발명자들에 의해 개발된 신품종 고구밸리 감자(Solanum tuberosum L., cv Gogu valley)는 국립종자관리원에 품종보호출원(출원번호:2002-13)해서 2004년에 국가품종으로 등록(등록번호: 1097)된 것으로서, 붉은색 표피의 감자 신품종으로, 일반 감자보다 생으로 먹기 편리하도록 개발되었고, 저장성이 뛰어나서 오랫동안 두어도 썩지 않는 특징을 가진다. Solanum tuberosum L., cv Gogu valley, developed by the present inventors, was filed with the National Protection Agency for seed protection (application number: 2002-13) and registered as a national variety in 2004 (registration number: 1097) As a new breed of red skinned potatoes, it was developed to be easier to eat raw than ordinary potatoes, and has excellent shelf life and does not rot even after long periods of time.
본 발명자들은 상기 신품종 감자인 고구밸리 감자(Solanum tuberosum L., cv Gogu valley)의 용도를 연구하던 중에 대한민국 공개특허공보 제2001-29185호에 감자가 항암작용을 갖는다는 기재와는 달리 일반 감자는 유의성이 있는 항암작용을 거의 나타내지 않으나, 고구밸리 감자 추출물은 암세포의 증식을 억제하는 작용이 매우 커서 암환자를 위한 건강기능식품으로 이용될 수 있음을 확인하고 본 발명을 완성하였다.The inventors of the new varieties potato potato potato ( Solanum tuberosum L., cv Gogu valley), while in the Republic of Korea Patent Publication No. 2001-29185 describes the potato has anti-cancer activity, while ordinary potatoes show little significant anti-cancer activity, Potato extract confirmed that the action of inhibiting the proliferation of cancer cells is very large can be used as a health functional food for cancer patients and completed the present invention.
본 발명은 신품종인 고구밸리 감자(Solanum tuberosum L., cv Gogu valley)를 이용하여 암을 예방할 수 있는 건강기능식품을 제공하는 것을 목적으로 한다.An object of the present invention to provide a health functional food that can prevent cancer by using a new varieties of Gogu Valley potatoes ( Solanum tuberosum L., cv Gogu valley).
상기와 같은 목적을 달성하기 위하여 본 발명은 고구밸리 감자(Solanum tuberosum L. cv. Gogu valley) 추출물을 함유하며, 암을 예방하고 암환자들에게 예후를 위한 건강기능식품을 제공한다.In order to achieve the above object, the present invention contains Solanum tuberosum L. cv. Gogu valley extract, prevents cancer and provides a health functional food for the prognosis to cancer patients.
본 발명에서 암세포 억제 활성 기능을 갖는 고구밸리 감자(Solanum tuberosum L. cv. Gogu valley) 추출물은 고구밸리 감자에 물 또는 알코올을 첨가하여 추출한 고구밸리 감자의 조추출물이거나 고구밸리 감자에 단백질 추출 버퍼(buffer)를 첨가하여 추출한 고구밸리 감자의 단백질 추출물을 함유하는 것을 의미한다. 상기 고구밸리 감자 추출물은 동결건조하여 분말 형태로 제조될 수 있다.In the present invention, Solanum tuberosum L. cv. buffer) is added to the protein extract of the sweet potato valley potato extracted. The sweet potato valley potato extract may be prepared in powder form by lyophilization.
본 발명에 따른 고구밸리 감자 추출물은 암세포 증식 억제에 의해 항암 효과를 갖는다. 또한 본 발명은 유전자 조작 작물(GMO)이 아닌 국가 품종으로 등록된 신품종 고구밸리 감자(Solanum tuberosum L., cv. Gogu valley)의 추출물에 의한 암세포의 증식 억제를 포함한다.Sweet potato valley potato extract according to the present invention has an anticancer effect by inhibiting cancer cell proliferation. In another aspect, the present invention includes inhibiting the proliferation of cancer cells by the extract of a new varieties Golan Valley potato ( Solanum tuberosum L., cv. Gogu valley) registered as a national variety, not a genetically modified crop (GMO).
본 발명의 고구밸리 감자(Solanum tuberosum L., cv. Gogu valley) 추출물은 독성시험 결과 건강기능식품으로 개발될 수 있으며, 또한 식품에 첨가하여 사용하기에 적합한 것이다.Golan valley potato extract of the present invention ( Solanum tuberosum L., cv. Gogu valley) extract can be developed as a health functional food as a result of toxicity test, it is also suitable for use in addition to food.
따라서 본 발명은 고구밸리 감자 추출물을 통상적인 기호성 식품 즉, 라면, 생면 등의 면류, 두부, 시리얼, 빵류, 츄잉 껌, 사탕, 과자류 중에 첨가하여 통상적으로 알려진 방법에 의하여 각종 식품을 제조할 수 있고, 또한 정제, 과립제, 환제, 경질캅셀제, 연질캅셀제 또는 액제 제형 등 일반적인 제형으로 제형화 될 수 있으며, 생즙, 파우치, 음료, 또는 다류로 제조될 수 있고, 상기한 성분 이외에 다른 성분은 제형에 따라 당업자가 적의하게 선택하여 배합 할 수 있다.Therefore, the present invention can be prepared by the conventional method known by adding a potato valley potato extract in the usual palatability food, that is, noodles, tofu, cereals, breads, chewing gum, candy, confectionary, such as ramen, raw noodles Tablets, granules, It may be formulated into a general formulation such as pills, hard capsules, soft capsules, or liquid formulations, and may be prepared in juice, pouches, beverages, or polysaccharides. You can mix.
본 발명의 암환자를 위한 건강기능식품은 상기 고구밸리 감자(Solanum tuberosum L., cv. Gogu valley) 추출물 식품의 주· 부원료로 하여 제조되거나 다른 식품에 첨가됨으로서 제조될 수 있다. 이 때 식품학적으로 허용되는 식품보조첨가제를 사용할 수 있다.Health functional foods for cancer patients of the present invention can be prepared as a main ingredient or a supplementary ingredient of Solanum tuberosum L., cv. At this time, food supplements that can be used food acceptable.
본 발명은 고구밸리 감자(Solanum tuberosum L., cv Gogu valley) 추출물이 사람의 피부 암세포와 위암 세포를 억제하는 데 유효한 효과가 있으며, 정상세포에 대해서는 세포독성 효과가 없으므로 보통 사람들의 암 예방 뿐 아니라 암 환자의 예후를 위한 건강기능식품으로 이용 될 수 있다.The present invention has an effective effect of Solanum tuberosum L., cv Gogu valley extracts in inhibiting human skin cancer and gastric cancer cells, and since there is no cytotoxic effect on normal cells, It can be used as a dietary supplement for the prognosis of cancer patients.
이하에서는 본 발명의 실시예를 통해 본 발명을 더욱 상세히 설명한다. 하기 실시예는 본 발명을 예시하기 위한 것이며, 본 발명의 내용이 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. The following examples are intended to illustrate the invention and are not intended to limit the scope of the invention.
<실시예 1> 고구밸리 감자 에탄올 추출물의 제조Example 1 Preparation of Potato Valley Potato Ethanol Extract
고구밸리 감자 33.2Kg을 에탄올 63L로 3회 추출하여 로터리 진공 증류기(Buchi 461)에서 감압 농축하고, 동결 건조하여 388g의 분말을 얻었다.33.2 Kg of sweet potato valley potatoes were extracted three times with 63 L of ethanol, concentrated under reduced pressure in a rotary vacuum still (Buchi 461), and lyophilized to obtain 388 g of powder.
<실시예 2> <Example 2> 고구밸리 감자 단백질 추출물의 제조Preparation of Sweet Potato Potato Protein Extract
공지의 방법(Ana Segura et al, Mol Plant Micro Interact., 12(1): 16-23, 1999)을 응용하여 고구밸리 감자의 괴경 20 Kg을 액체질소가 첨가된 상태에서 막자사발을 이용하여 분말로 분쇄한 후, 10 mM 트리스-염산, 1.5 M 리튬 클로라이드(10mM Tris-HCl, 1.5 M LiCl pH7.2) 혼합용매로 고구밸리 감자의 단백질을 추출하고, 냉동 감압 건조하여 건조분말을 얻었다.By applying a known method (Ana Segura et al, Mol Plant Micro Interact ., 12 (1): 16-23, 1999), 20 kg of tubers of sweet potato valley potatoes were powdered using a mortar and pestle in a state where liquid nitrogen was added. After pulverizing with 10 mM Tris-hydrochloric acid, 1.5 M lithium chloride (10 mM Tris-HCl, 1.5 M LiCl pH 7.2) mixed solvent, the protein of the potato valley potato was extracted, and dried under reduced pressure to obtain a dry powder.
<비교예 1> Comparative Example 1 일반감자 에탄올 추출물의 제조Preparation of Common Potato Ethanol Extract
실시예 1과 동일한 방법으로 일반감자로부터 추출하여, 냉동 감압 건조하여 건조분말을 얻었다.In the same manner as in Example 1, the mixture was extracted from a potato, dried under reduced pressure and dried to obtain a dry powder.
<실험예 1> 고구밸리 감자 추출물의 함암 활성 측정Experimental Example 1 Measurement of Hamam Activity of Potato Valley Potato Extract
가. 실험재료 및 실험 세포주end. Experimental Materials and Experimental Cell Lines
실험재료로는 상기 실시예 1, 2 및 비교예 1에서 제조된 감자의 추출물을 사용하였고, 실험 세포주는 한국 세포주 은행으로부터 분양받아 일정한 조건(온도 : 37℃, 이산화탄소 : 5%)하에서 충분하게 자란 사람 피부암 세포인 지-361(G-361)과 사람 위암세포인 에이지에스(AGS)를 준비하였다.As an experimental material, the extracts of the potatoes prepared in Examples 1 and 2 and Comparative Example 1 were used, and the experimental cell line was grown from a bank of Korean cell lines and sufficiently grown under constant conditions (temperature: 37 ° C., carbon dioxide: 5%). G-361 (G-361), a human skin cancer cell, and AGS, a human gastric cancer cell, were prepared.
나. 실험방법I. Experiment method
세포주를 96-웰 플레이트 (96 well plate) 각 웰당 2 X 103가 되도록 희석하여 암세포를 포함한 메디아 알피엠아이-1641 (RPMI-1640) 100 마이크로리터를 플레이트에 분주한 후 37℃ 배양기에서 세포주가 부착할때까지 배양하였다. 세포주가 부착이 된 후 실시예 1, 2 및 비교예 1에서 제조된 감자 추출물을 각 웰당 100 마이크로 그람씩 넣고, 37℃ 배양기에서 24 시간 배양하였다. 그리고 각각의 웰에 50 마이크로 그람의 3-(4,5-디메틸-2-티아졸일)-2,5-디페닐-2H-테트라졸리움 부로마이드(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide)용액을 넣 고 37℃ 배양기에서 4시간 동안 배양하였다. 각 웰의 흡광도를 엘라이자 리더 (ELISA reader)를 이용하여 570 나오미터(nm)에서 그 발색정도를 측정하고 표 1 및 표 2에 나타내었다.Dilute the cell line to 2 X 10 3 for each well of the 96-well plate, dispense 100 microliters of Media-RPM-1641 (RPMI-1640) containing cancer cells onto the plate, and attach the cell line in a 37 ° C incubator. Incubate until After the cell lines were attached, the potato extracts prepared in Examples 1, 2 and Comparative Example 1 were put in 100 micrograms per well, and cultured in a 37 ° C. incubator for 24 hours. And 50 micrograms of 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H-tetrazolium bromide (3- (4,5-dimethyl-2-thiazolyl) in each well. ), 2,5-diphenyl-2H-tetrazolium bromide) solution was added and incubated for 4 hours at 37 ℃ incubator. The absorbance of each well was measured at 570 nm (nm) using an ELISA reader and shown in Tables 1 and 2.
다. 실험결과All. Experiment result
사람의 피부암 세포주인 지-361(G-361)과 사람 위암세포인 에이지에스(AGS) 두 세포주가 본 발명에 의한 실시예 1 및 2에서 제조된 고구밸리 감자 추출물에 의해 억제됨을 확인하였다.Human skin cancer cell line G-361 (G-361) and human gastric cancer cell AGS (AGS) two cell lines were confirmed to be inhibited by the extract of potato yam produced in Examples 1 and 2 according to the present invention.
상기 표 1 및 표 2에서 알 수 있는 바와 같이, 본 발명에 의한 실시예 1 및 2는 사람의 피부암 및 위암세포에 대하여 억제 효과를 나타내어 항암 활성을 가짐을 알 수 있으나, 일반 감자인 비교예 1은 민간요법으로 구전되어 오고 있는 항암 효과와는 달리 거의 효과를 나타내지 못함을 알 수 있다.As can be seen in Table 1 and Table 2, Examples 1 and 2 according to the present invention shows an inhibitory effect on human skin cancer and gastric cancer cells, but it can be seen that it has anti-cancer activity, Comparative Example 1 is a regular potato Unlike the anti-cancer effects that have been orally treated by folk remedies, it can be seen that they have little effect.
그러므로 신품종인 고구밸리 감자(Solanum tuberosum L., cv. Gogu valley) 는 일반 감자와는 달리 항암 활성에 매우 효과가 뛰어난 것임을 확인 할 수 있다.Therefore, the new varieties, Golan valley ( Solanum tuberosum L., cv. Gogu valley), can be seen that the anti-cancer activity is very effective unlike the other potatoes.
<실험예 2> 세포독성 측정Experimental Example 2 Cytotoxicity Measurement
일정한 조건(온도 : 37℃, 이산화탄소 : 5%)하에서 충분하게 자란 사람의 정상 각질형성 세포주(HaCaT)를 96-웰 플레이트에 2 X 103가 되도록 희석하여 정상세포를 포함한 메디아 디이엠이 (DEME) 100 마이크로리터를 플레이트에 분주한 후 37℃ 배양기에서 세포주가 부착할 때까지 배양하였다. 세포주가 부착이 된 후 상기 실시예 2에서 제조된 감자의 단백질 추출물을 상기 웰에 100 마이크로 그람 넣고, 37℃ 배양기에서 24 시간 배양하였다. 그리고 웰에 50 마이크로 그람의 엠티티 (MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide)용액을 넣고 37℃ 배양기에서 4시간 동안 배양하였다. 웰의 흡광도를 엘라이자 리더 (ELISA reader)를 이용하여 570 나오미터(nm)에서 그 발색정도를 측정하여 표 3에 나타내었다.Under normal conditions (temperature: 37 ° C, carbon dioxide: 5%), the normal keratinocyte cell line (HaCaT) of humans grown enough to dilute to 2 x 10 3 in 96-well plate to median DM containing normal cells (DEME ) 100 microliters were aliquoted onto the plate and incubated in a 37 ° C. incubator until the cell lines adhered. After the cell line was attached, 100 micrograms of protein extract of the potato prepared in Example 2 was placed in the well, and cultured in a 37 ° C. incubator for 24 hours. And 50 micrograms of empty (MTT, 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H-tetrazolium bromide) solution was added to the wells and incubated for 4 hours at 37 ℃ incubator. The absorbance of the wells was measured in the 570 nm (nm) using an ELISA reader, and the results are shown in Table 3.
상기 표 3에서 알 수 있는바와 같이, 본 발명에 의한 고구밸리 감자 추출물은 사람의 정상세포에는 독성을 보이지 않아 이러한 인체에 악영향을 미치지 않을 것으로 판단된다.As can be seen in Table 3, the sweet potato valley according to the present invention potato The extract does not appear to be toxic to normal cells of humans, so it is not considered to adversely affect the human body.
도 1은 본 발명에 의한 고구밸리 감자(Solanum tuberosum L., cv. Gogu valley)의 실물 사진을 나타낸 것이다.1 is a potato potato potato Solanum according to the present invention tuberosum L., cv. A real photograph of the Gogu valley is shown.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080039284A KR100883566B1 (en) | 2008-04-28 | 2008-04-28 | The healthy and funtional foods for the cancer prevention of using new type of solanum tuberosum l cv. gogu valley |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080039284A KR100883566B1 (en) | 2008-04-28 | 2008-04-28 | The healthy and funtional foods for the cancer prevention of using new type of solanum tuberosum l cv. gogu valley |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100883566B1 true KR100883566B1 (en) | 2009-02-13 |
Family
ID=40681605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080039284A KR100883566B1 (en) | 2008-04-28 | 2008-04-28 | The healthy and funtional foods for the cancer prevention of using new type of solanum tuberosum l cv. gogu valley |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100883566B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100963094B1 (en) | 2008-04-28 | 2010-06-10 | (주)포테이토밸리 | Pharmaceutical composition for the anticancer comprising the extracted protein or peptide from Solanum tuberosum L cv. Gogu Valley |
KR20220096691A (en) * | 2020-12-31 | 2022-07-07 | 강원대학교산학협력단 | Processing technology for increasing bioactive compounds in potato |
KR102616633B1 (en) * | 2023-05-24 | 2023-12-21 | 강원대학교산학협력단 | Optimization processing and mixing technology of colored potato for increasing antidiabetic and antiobesity activity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040093553A (en) * | 2003-04-30 | 2004-11-06 | 주식회사 하이닉스반도체 | Method for forming metal line of semiconductor device |
KR20070071666A (en) * | 2005-12-30 | 2007-07-04 | 주식회사 팬택 | Slider hinge structure of mobile telecommunication terminal |
KR20080039285A (en) * | 2006-10-31 | 2008-05-07 | 인벤티오 아게 | Lift with two lift cages disposed one above the other in a lift shaft |
-
2008
- 2008-04-28 KR KR1020080039284A patent/KR100883566B1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040093553A (en) * | 2003-04-30 | 2004-11-06 | 주식회사 하이닉스반도체 | Method for forming metal line of semiconductor device |
KR20070071666A (en) * | 2005-12-30 | 2007-07-04 | 주식회사 팬택 | Slider hinge structure of mobile telecommunication terminal |
KR20080039285A (en) * | 2006-10-31 | 2008-05-07 | 인벤티오 아게 | Lift with two lift cages disposed one above the other in a lift shaft |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100963094B1 (en) | 2008-04-28 | 2010-06-10 | (주)포테이토밸리 | Pharmaceutical composition for the anticancer comprising the extracted protein or peptide from Solanum tuberosum L cv. Gogu Valley |
KR20220096691A (en) * | 2020-12-31 | 2022-07-07 | 강원대학교산학협력단 | Processing technology for increasing bioactive compounds in potato |
KR102511666B1 (en) * | 2020-12-31 | 2023-03-17 | 강원대학교산학협력단 | Processing technology for increasing bioactive compounds in potato |
KR102616633B1 (en) * | 2023-05-24 | 2023-12-21 | 강원대학교산학협력단 | Optimization processing and mixing technology of colored potato for increasing antidiabetic and antiobesity activity |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Prasad et al. | Horse gram-an underutilized nutraceutical pulse crop: a review | |
KR101158856B1 (en) | Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of Glycine max leaves as an active ingredient | |
JP4980429B2 (en) | Cancer prevention and treatment composition comprising arazyme as active ingredient | |
KR20220054781A (en) | Pharmaceutical composition for preventing or treating glioblastoma comprising Phellodendron amurense Ruprecht or Scutellaria baicalensis | |
KR100883566B1 (en) | The healthy and funtional foods for the cancer prevention of using new type of solanum tuberosum l cv. gogu valley | |
KR101902932B1 (en) | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum | |
Singh et al. | Bioactive Compounds, Pharmacological Properties, and Utilization of Pomegranate (Punica granatum L.): A Comprehensive Review. | |
KR100963094B1 (en) | Pharmaceutical composition for the anticancer comprising the extracted protein or peptide from Solanum tuberosum L cv. Gogu Valley | |
KR101242635B1 (en) | Composition for Prevention or Treatment of Osteoporosis Comprising Extract of Selaginellae Herba | |
KR101706552B1 (en) | A stomach cancer treatment composition comprising extract of job's tears and preparation methods thereof | |
Edo et al. | Bioactive Compounds and Biological Activities of Tiger Nut (Cyperus esculentus L.) | |
JP2009029748A (en) | Colon cancer suppressing agent using chinese yam | |
Gandhi et al. | Bioactive compounds of amaranth (Genus Amaranthus) | |
KR20160036825A (en) | Health functional food for preventing or treatment tumor | |
KR101398737B1 (en) | Composition for preventing and/or treating tumor containing component originating in the bark of tree belonging to the genus acacia | |
KR100836711B1 (en) | Pharmaceutical composition containing arazyme for the prevention of liver dysfunction | |
KR100539456B1 (en) | Composition For Preventing And Treating Cancer Comprising The Extract Of Sophorae Fructus | |
KR20090110602A (en) | The composition for the treatment of cancers and inhibition of metastasis containing extracts and fractions of the magnolia obovata | |
KR102197352B1 (en) | Method for producing a composition for reducing urushiol content, a composition prepared by the method for producing the composition, an anti-obesity agent, an inhibitor of fat accumulation, and an inhibitor of increasing the amount of leptin in blood | |
KR102621972B1 (en) | Method for producing gold nanoparticle using bacterial strain and phyllanthus emblica extract and pharmaceutical composition for treating cancer comprising the gold nanoparticle | |
KR102612962B1 (en) | Pharmaceutical composition for preventing and treating osteoarthritis | |
KR101532307B1 (en) | Pharmaceutical compositions having anti-metastasis activity comprising extract of bambusae caulis in taeniam | |
Seke et al. | 22 Black Plum (Vitex doniana) | |
KR20160083808A (en) | Health fuctional food composition for preventing or improving life style diseases or liver diseases comprising Fagopyrum tataricum as effective component | |
KR101239320B1 (en) | Composition comprising extract of Momordica charantia for anti-cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130102 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131205 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |